RecruitingPhase 3NCT06793397
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder
Sponsor
Cybin IRL Limited
Enrollment
330 participants
Start Date
Dec 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria12
- Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD.
- Moderate to severe depression at Screening.
- Participants have been on a stable dose of antidepressant medication at an adequate dose in the last 4 weeks prior to Screening.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participants with well controlled hypertension.
- Participant is able to refrain from smoking during the dosing session.
- Participants must use a condom plus spermicide during the trial and for 12 weeks afterwards.
- Participants of childbearing potential must agree to use a highly effective method of and a negative pregnancy test at Screening and Day -1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria18
- Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \[including dyspepsia or gastroesophageal reflux disease\], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5 hydroxytryptophan or St John's Wort within prior to trial medication administration.
- Strenuous exercise prior to each clinic visit.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Interventions
DRUGCYB003
CYB003 is a deuterated psilocin analog.
BEHAVIORALPsychological Support
Manualized psychological support performed by facilitator.
Locations(67)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06793397
Related Trials
A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression
NCT073962721 location
IMST for Dementia Risk Reduction
NCT073497061 location
Cerebellar Stimulation and Cognitive Control
NCT032171101 location
Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan
NCT070159441 location
Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care
NCT073648253 locations